Compare EE & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EE | INBX |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | 1046 | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.7M |
| IPO Year | 2022 | 2024 |
| Metric | EE | INBX |
|---|---|---|
| Price | $35.79 | $109.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $39.20 | ★ $150.00 |
| AVG Volume (30 Days) | 362.3K | ★ 586.3K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,228,263,000.00 | $1,300,000.00 |
| Revenue This Year | $23.59 | N/A |
| Revenue Next Year | $24.37 | N/A |
| P/E Ratio | $97.89 | ★ N/A |
| Revenue Growth | 44.26 | ★ 550.00 |
| 52 Week Low | $21.29 | $12.80 |
| 52 Week High | $43.18 | $155.29 |
| Indicator | EE | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 50.41 |
| Support Level | $35.10 | $69.30 |
| Resistance Level | $43.18 | $155.29 |
| Average True Range (ATR) | 1.44 | 13.20 |
| MACD | 0.26 | -3.55 |
| Stochastic Oscillator | 80.54 | 23.22 |
Excelerate Energy Inc. offers comprehensive LNG solutions by providing integrated services throughout the LNG value chain. The company delivers a full range of regasification services, including Floating Storage and Regasification Units (FSRUs), infrastructure development, and the supply of LNG and natural gas. With operational presence in several countries - Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States. The company generates revenue through Terminal Services, as well as from LNG, gas, and power. These revenues are derived from its vertically integrated activities in LNG sourcing, transportation, regasification, and power generation.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.